Pazopanib for the treatment of breast cancer

被引：13

作者：

Amiri-Kordestani, Laleh ^{[2
]}

Tan, Antoinette R. ^{[3
]}

Swain, Sandra M. ^{[1
]}

机构：

[1] Washington Hosp Ctr, Washington Canc Inst, MedStar Hlth, Washington, DC 20010 USA

[2] NCI, Bethesda, MD 20892 USA

[3] Canc Inst New Jersey,Med Oncol, New Brunswick, NJ USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2012年 / 21卷 / 02期

关键词：

breast cancer; pazopanib; PDGFR; tyrosine kinase inhibitor; VEGF; VEGFR; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; BETA-RECEPTOR EXPRESSION; TUMOR ANGIOGENESIS; FACTOR PDGF; PHASE-II; PROGNOSTIC-SIGNIFICANCE; SUNITINIB MALATE; CARCINOMA; SURVIVAL;

D O I：

10.1517/13543784.2012.652304

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Several clinical trials have shown clinical benefit of angiogenesis inhibitors in the treatment of solid tumors. Pazopanib is a multitargeted tyrosine kinase inhibitor that is currently approved for the treatment of patients with advanced renal cell carcinoma (RCC). Areas covered: In this article, the clinical development of pazopanib as it relates to breast cancer is reviewed including its evaluation in clinical trials and side effect profile. Preclinical data show the anti-tumor activity of pazopanib in animal models. Several trials of pazopanib monotherapy and combination therapy in breast cancer have been completed or are underway. Expert opinion: The development of biomarkers predictive of response and toxicity to angiogenesis inhibitors remains a challenging endeavor and is necessary to help guide treatment decision.

引用

页码：217 / 225

页数：9

共 69 条

[1] PLATELET-DERIVED GROWTH-FACTOR (PDGF) IN PLASMA OF BREAST-CANCER PATIENTS - CORRELATION WITH STAGE AND RATE OF PROGRESSION [J].

ARIAD, S ;

SEYMOUR, L ;

BEZWODA, WR .

BREAST CANCER RESEARCH AND TREATMENT, 1991, 20 (01) :11-17

[2]

Balagula Y, 2011, INVEST NEW DRUGS

[3] Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. [J].

Baruchel, S. ;

Wu, B. ;

Mokhtari, R. B. ;

Bender, J. L. Glade ;

DuBois, S. G. ;

Widemann, B. C. ;

Park, J. R. ;

Stempak, D. ;

Ahern, C. H. ;

Weigel, B. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[4]

Baselga J, 2009, 15 C EUR CANC ORG EC

[5]

Bhardwaj B, 1996, CLIN CANCER RES, V2, P773

[6] Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer [J].

Bianchi, Giulia ;

Loibl, Sibylle ;

Zamagni, Claudio ;

Salvagni, Stefania ;

Raab, Guenter ;

Siena, Salvatore ;

Laferriere, Nicole ;

Pena, Carol ;

Lathia, Chetan ;

Bergamini, Loredana ;

Gianni, Luca .

ANTI-CANCER DRUGS, 2009, 20 (07) :616-624

[7] SYNTHESIS AND SECRETION OF PLATELET-DERIVED GROWTH-FACTOR BY HUMAN-BREAST CANCER CELL-LINES [J].

BRONZERT, DA ;

PANTAZIS, P ;

ANTONIADES, HN ;

KASID, A ;

DAVIDSON, N ;

DICKSON, RB ;

LIPPMAN, ME .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5763-5767

[8]

Burris III HA, 2009, MOL TARGETS CANC S1, V8

[9] Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].

Burstein, Harold J. ;

Elias, Anthony D. ;

Rugo, Hope S. ;

Cobleigh, Melody A. ;

Wolff, Antonio C. ;

Eisenberg, Peter D. ;

Lehman, Mary ;

Adams, Bonne J. ;

Bello, Carlo L. ;

DePrimo, Samuel E. ;

Baum, Charles M. ;

Miller, Kathy D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816

[10] c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? [J].

Carvalho, S ;

Silva, AOE ;

Milanezi, F ;

Ricardo, S ;

Leitao, D ;

Amendoeira, I ;

Schmitt, FC .

JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (10) :1075-1079

← 1 2 3 4 5 6 7 →